JP2023542093A5 - - Google Patents

Info

Publication number
JP2023542093A5
JP2023542093A5 JP2023515686A JP2023515686A JP2023542093A5 JP 2023542093 A5 JP2023542093 A5 JP 2023542093A5 JP 2023515686 A JP2023515686 A JP 2023515686A JP 2023515686 A JP2023515686 A JP 2023515686A JP 2023542093 A5 JP2023542093 A5 JP 2023542093A5
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
pharmaceutical composition
composition according
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542093A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/116498 external-priority patent/WO2022052874A1/zh
Publication of JP2023542093A publication Critical patent/JP2023542093A/ja
Publication of JP2023542093A5 publication Critical patent/JP2023542093A5/ja
Pending legal-status Critical Current

Links

JP2023515686A 2020-09-09 2021-09-03 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 Pending JP2023542093A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010939961 2020-09-09
CN202010939961.4 2020-09-09
PCT/CN2021/116498 WO2022052874A1 (zh) 2020-09-09 2021-09-03 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用

Publications (2)

Publication Number Publication Date
JP2023542093A JP2023542093A (ja) 2023-10-05
JP2023542093A5 true JP2023542093A5 (cg-RX-API-DMAC7.html) 2024-09-06

Family

ID=80632631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515686A Pending JP2023542093A (ja) 2020-09-09 2021-09-03 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用

Country Status (7)

Country Link
US (1) US20230321074A1 (cg-RX-API-DMAC7.html)
EP (1) EP4212160A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023542093A (cg-RX-API-DMAC7.html)
KR (1) KR20230066401A (cg-RX-API-DMAC7.html)
CN (3) CN121943909A (cg-RX-API-DMAC7.html)
TW (1) TW202214243A (cg-RX-API-DMAC7.html)
WO (1) WO2022052874A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117597124A (zh) * 2021-07-08 2024-02-23 深圳微芯生物科技股份有限公司 西奥罗尼及其联合用药治疗乳腺癌的用途
KR20240153590A (ko) * 2022-02-24 2024-10-23 아케소 파마슈티컬스, 인코포레이티드 항-ctla4-항-pd-1 이중특이적 항체 및 치아우라닙을 포함하는 약제학적 조성물
CN116889565A (zh) * 2022-04-07 2023-10-17 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
CN115177620A (zh) * 2022-07-18 2022-10-14 厦门大学附属第一医院 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用
EP4578449A4 (en) * 2022-08-24 2026-01-21 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND MICROTUBULE INHIBITOR AND COMBINED USE
WO2024055179A1 (zh) * 2022-09-14 2024-03-21 同济大学苏州研究院 Pd-1抗体药物继发耐药免疫抑制靶点及应用
CN115845052B (zh) * 2022-12-28 2023-12-29 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗结肠癌中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211901B2 (en) * 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
US20160303231A1 (en) 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN107868044B (zh) * 2016-09-27 2020-10-16 深圳微芯生物科技股份有限公司 一种非溶剂化晶体及其制备方法与应用
TWI764943B (zh) 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
CN106963948A (zh) 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用
TW201902514A (zh) * 2017-06-05 2019-01-16 大陸商江蘇恆瑞醫藥股份有限公司 Pd-1抗體與vegf配體或vegf受體抑制劑聯合在製備治療腫瘤的藥物中的用途
WO2019096194A1 (zh) * 2017-11-16 2019-05-23 江苏恒瑞医药股份有限公司 Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN109893654B (zh) * 2017-12-11 2021-07-27 江苏恒瑞医药股份有限公司 Vegfr抑制剂治疗肿瘤的方法
CN113975264A (zh) * 2018-04-16 2022-01-28 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
CN110833544B (zh) * 2018-08-17 2022-08-09 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途
CN109908143B (zh) * 2018-12-18 2021-11-19 厦门大学附属第一医院 西奥罗尼在制备治疗急性髓系白血病药物的新用途
CN112741905A (zh) * 2019-10-30 2021-05-04 江苏恒瑞医药股份有限公司 Vegfr抑制剂与抗pd-1抗体联合在制备治疗妊娠滋养细胞肿瘤的药物中的用途
KR20240153590A (ko) * 2022-02-24 2024-10-23 아케소 파마슈티컬스, 인코포레이티드 항-ctla4-항-pd-1 이중특이적 항체 및 치아우라닙을 포함하는 약제학적 조성물

Similar Documents

Publication Publication Date Title
JP2014527042A5 (cg-RX-API-DMAC7.html)
HRP20202065T1 (hr) Kristalni oblik inhibitora mdm2
FI3986890T3 (fi) Bentsisoksatsolisulfonamidijohdannaisia
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
JP2015520753A5 (cg-RX-API-DMAC7.html)
JP2011126896A5 (cg-RX-API-DMAC7.html)
HRP20231163T1 (hr) Prolijekovi glutaminskih analoga
HRP20100166T1 (hr) Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze
HRP20150771T1 (hr) Spoj za inhibiciju notch signalnog puta
RU2014147105A (ru) 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения
JP2020536066A5 (cg-RX-API-DMAC7.html)
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
RU2016108667A (ru) Комбинированная терапия для лечения рака
HRP20160014T1 (hr) Derivati 1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamida kao inhibitori fosfatidilinozitol 3-kinaze (pi3k), koji su korisni u lijeäśenju proliferativnih bolesti
RU2014101626A (ru) Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
RU2010142390A (ru) Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения
JP2021534158A5 (cg-RX-API-DMAC7.html)
JP2015536964A5 (cg-RX-API-DMAC7.html)
JP2017526662A5 (cg-RX-API-DMAC7.html)
JP2015536986A5 (cg-RX-API-DMAC7.html)
RU2019142694A (ru) Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний
JP2016522202A5 (cg-RX-API-DMAC7.html)
JP2021502415A5 (cg-RX-API-DMAC7.html)
JP2014532751A5 (cg-RX-API-DMAC7.html)
AU2017214572A1 (en) Glucose conjugates of triptolide, analogs and uses thereof